71 related articles for article (PubMed ID: 12382028)
41. Thyroid hormone export from cells: contribution of P-glycoprotein.
Mitchell AM; Tom M; Mortimer RH
J Endocrinol; 2005 Apr; 185(1):93-8. PubMed ID: 15817830
[TBL] [Abstract][Full Text] [Related]
42. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells.
Wan CK; Zhu GY; Shen XL; Chattopadhyay A; Dey S; Fong WF
Biochem Pharmacol; 2006 Sep; 72(7):824-37. PubMed ID: 16889754
[TBL] [Abstract][Full Text] [Related]
43. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
44. Histone deacetylase inhibitor apicidin-mediated drug resistance: involvement of P-glycoprotein.
Kim YK; Kim NH; Hwang JW; Song YJ; Park YS; Seo DW; Lee HY; Choi WS; Han JW; Kim SN
Biochem Biophys Res Commun; 2008 Apr; 368(4):959-64. PubMed ID: 18275843
[TBL] [Abstract][Full Text] [Related]
45. Tissue factor expression and multidrug resistance in cancer: two aspects of a common cellular response to a hostile milieu.
Lwaleed BA; Cooper AJ
Med Hypotheses; 2000 Dec; 55(6):470-3. PubMed ID: 11090292
[TBL] [Abstract][Full Text] [Related]
46. Modulation of doxorubicin sensitivity by a novel organic compound, oxalyl bis (N-phenyl) hydroxamic acid on acetyl aminofluorene-induced preneoplastic hepatocytes.
Choudhuri SK; Majumder S
Cancer Lett; 2003 Dec; 202(1):25-34. PubMed ID: 14643023
[TBL] [Abstract][Full Text] [Related]
47. Reversers of the multidrug resistance transporter P-glycoprotein.
Stein WD
Curr Opin Investig Drugs; 2002 May; 3(5):812-7. PubMed ID: 12090558
[TBL] [Abstract][Full Text] [Related]
48. A novel tin based hydroxamic acid complex induces apoptosis through redox imbalance and targets Stat3/JNK1/MMP axis to overcome drug resistance in cancer.
Banerjee K; Choudhuri SK
Free Radic Res; 2021 Oct; 55(9-10):1018-1035. PubMed ID: 34865583
[TBL] [Abstract][Full Text] [Related]
49. Intra- and intercellular distribution of mitochondrial probes and changes after treatment with MDR modulators.
Diaz G; Diana A; Falchi AM; Gremo F; Pani A; Batetta B; Dessì S; Isola R
IUBMB Life; 2001 Feb; 51(2):121-6. PubMed ID: 11463164
[TBL] [Abstract][Full Text] [Related]
50. The molecular perspective: the multidrug transporter.
Goodsell DS
Oncologist; 1999; 4(5):428-9. PubMed ID: 10551560
[No Abstract] [Full Text] [Related]
51. [Pharmacological study of p-butoxyphenylacethydroxamic acid (CP 1044 J3). II. Toxicological research].
Lambelin G; Buu-Hoi NP; Mees G; Thiriaux J; Huriaux M
Med Pharmacol Exp Int J Exp Med; 1966; 15(6):545-54. PubMed ID: 6013064
[No Abstract] [Full Text] [Related]
52. [Pharmacological studies on decanohydroxamic acid. IV. Subacute oral toxicity on rats].
Kitagawa H; Yoshida S; Abe M; Fukuda Y
Yakugaku Zasshi; 1965 Nov; 85(11):1012-6. PubMed ID: 5893830
[No Abstract] [Full Text] [Related]
53. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
54. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
55. P-glycoprotein activity and biological response.
Vaalburg W; Hendrikse NH; Elsinga PH; Bart J; van Waarde A
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):257-60. PubMed ID: 16043202
[TBL] [Abstract][Full Text] [Related]
56. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance.
Boumendjel A; Di Pietro A; Dumontet C; Barron D
Med Res Rev; 2002 Sep; 22(5):512-29. PubMed ID: 12210557
[TBL] [Abstract][Full Text] [Related]
57. Deactivation of P-glycoprotein by a novel compound, oxalyl bis (N-phenyl) hydroxamic acid.
Choudhuri SK
Neoplasma; 2002; 49(4):272-7. PubMed ID: 12382028
[TBL] [Abstract][Full Text] [Related]
58. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
